SUBSCRIBE
SUBSCRIBE
News   FDA

Bristol-Myers Squibb Company Obtains Japan Approval For Baraclude, Treatment For Chronic Hepatitis B Patients

August 4, 2006 | 
1 min read
Tokyo, Aug 3, 2006 (JCN) - Bristol-Myers Squibb Japan announced on July 26 that its Baraclude - generic name: entecavir - had been certifiied by Japan's Health, Labor and Welfare Ministry.
FDA Approvals Asia
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Regulatory
In Change That Pushed Pazdur Out, FDA May Lower Clinical Trial Requirements
December 5, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Red round circle with a pause button or icon against yellow background.
Regulatory
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals
December 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Courtesy of uniQure
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
December 4, 2025
 · 
2 min read
 · 
Heather McKenzie
Business people shaking hand in China.
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
December 4, 2025
 · 
2 min read
 · 
Tristan Manalac